NEWS
Study Questions Value of Prostate Cancer Screening
Widespread screening for prostate cancer over the past 3 decades using the prostate-specific antigen (PSA) test has led to a flood of men being diagnosed with and treated for prostate cancer that never would have harmed them, according to a new study. The jump in diagnoses was most pronounced among younger men, with rates more than tripling for men aged 50 to 59 and increasing seven-fold for those aged 50 and younger. The study was published online August 31 in the Journal of the National Cancer Institute (JNCI). Read more > >
Genetic Study Points to Potential Treatment for Melanoma
Clinical trial is being planned to test lapatinib in selected patientsChemotherapy Provides Longer Survival than Enzyme Therapy for Pancreatic Cancer
Trial testing the Gonzalez regimen was one of the first to compare survival following standard or alternative treatmentsDenosumab Keeps Bones Strong during Prostate Cancer Treatment
The monoclonal antibody prevented fractures in men receiving common therapy and is under consideration by FDAWeight Lifting Reduces Lymphedema Symptoms after Breast Cancer
Finding contradicts past recommendations to avoid the activityIn West African Women, Majority of Breast Cancers Have a Poor Prognosis
Disparate rates may be due to a combination of biological and non-biological factors
COMMENTARY
Guest Director's Update: Finding the Right Mix of Care Providers for Cancer Patients
Whether treatment is received at a comprehensive cancer center or, as is the case for the majority of patients, at a community hospital, it's unclear who is directing and coordinating the clinical care decisions for those undergoing active treatment. With the expected increase in cancer incidence (due in large part to an aging population), the health care community must begin to focus on this critically important issue. Read more > >
A Conversation about Personal Genomic Tests with Dr. Muin Khoury
The director of CDC's National Office of Public Health Genomics discusses the science behind personal genomic tests. These tests, which include "genetic risk profiles" for cancer and other common diseases, are sold directly to consumers. Read more > >
| Subscribe Now! |
A MESSAGE TO READERS
NCI Cancer Bulletin Articles
in Spanish
Beginning September 15, NCI will publish the Boletín del Instituto Nacional del Cáncer, a modified Spanish-language translation of selected articles previously published in the NCI Cancer Bulletin. This new resource offers Spanish-speaking readers up-to-date articles on the latest research advances in the prevention, treatment, and understanding of cancer. To receive the monthly selection, email nciboletin@mail.nih.gov or view the articles at http://www.cancer.gov/espanol.
IN DEPTH
In Cancer, Hitting a Target Called Hedgehog
A new type of cancer drug shows promise in an early stage clinical trial
Growing Pains: Palliative Care Making Gains
Evidence builds to make a case for palliative care's value, but challenges remain
Proton Therapy for Cancer: A New Technology Brief
Enthusiasm for this promising therapy may be getting ahead of the research
Featured Clinical Trial: Testing a New Drug in Advanced BRCA-related Cancer
Is the combination of AZD2281 and carboplatin safe for women with BRCA-related breast or ovarian cancer?
UPDATES
FDA Update
- New FDA Center and Advisory Committee Launch Regulation of Tobacco
- Agency Issues New Rules for Obtaining Investigational Drugs
Notes
- Dr. William Dahut Named CCR Clinical Director
- NCI Tobacco Control Monograph Addresses Genetics of Nicotine Dependence
- CRCHD Hosted Professional Development and Diversity Training Conference
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
